Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

PHASE4CompletedINTERVENTIONAL
Enrollment

54,115

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

July 6, 2024

Study Completion Date

July 6, 2024

Conditions
MalariaMalaria Vaccines
Interventions
DIAGNOSTIC_TEST

Assessment of body temperature

Axillary body temperature of all participants recorded by a digital thermometer at the time of survey.

PROCEDURE

Blood sampling

Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.

Trial Locations (12)

2208

GSK Investigational Site, Ouagadougou

12500

GSK Investigational Site, Dakar

16556

GSK Investigational Site, Dakar

40100

GSK Investigational Site, Kisumu

GSK Investigational Site, Nairobi

40102

GSK Investigational Site, Kisumu

Unknown

GSK Investigational Site, Nouna

GSK Investigational Site, Kintampo

GSK Investigational Site, Navrongo

GSK Investigational Site, Chikwawa

GSK Investigational Site, Mangochi

GSK Investigational Site, Amani

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

lead

GlaxoSmithKline

INDUSTRY